SOURCE: Optigenex, Inc.

February 18, 2010 08:00 ET

Optigenex Inc. Renews Its Agreement With RFI Ingredients for Marketing and Sale of AC-11® in Retail and Direct to Physician Channels (Financial Terms Were Not Disclosed)

NEW YORK, NY--(Marketwire - February 18, 2010) - Optigenex Inc. (PINKSHEETS: OPGX) announced today the signing with RFI, LLC of a new, non-exclusive Supply and Trademark License Agreement for the territory of North America. The new agreement renews the parties' several year-long business relationship and extends continuing rights to RFI to manufacture and market dietary supplement products containing AC-11® (formerly known as C-Med-100®). Both parties anticipate that this timely recommitment will reap mutual benefits, as the growing body of AC-11® scientific validation recently has opened several new doors for capitalizing on Optigenex's patented technology, especially in the novel field of advanced, oral-based sun care products.

Jeff Wuagneux, President and CEO of RFI, stated, "We are very excited to continue our work with the management of Optigenex to promote the AC-11® product into the natural healthcare industry. Over the past several years we have come to value the science behind AC-11®, and Optigenex's commitment to furthering the clinical validation of the technology. RFI is dedicated to promoting and marketing science based products, and we feel confident that AC-11® will have a great impact as a key strategic component in both the oral-based sun care market, as well as the DNA repair and antioxidant categories."

Daniel Zwiren, President and CEO of Optigenex, added, "We are pleased with the opportunity to renew our excellent relationship with RFI. Jeff and his team have demonstrated an impressive understanding and command of the market, as well as a strong loyalty to AC-11® technology over the past two years in the direct to physician's channel. The signing of this expanded agreement was an easy decision for us, because RFI in an impressive fashion has grown its business vertically from wholesale ingredient supplier to a finished product, direct to consumer marketing company. We are confident that RFI is positioned to market AC-11® on a large scale to health conscious, educated consumers in North America."

About RFI, LLC:

RFI, LLC is a U.S. based (New York, Colorado) Life Science Development and Commercialization Company offering a pipeline of novel compounds and proprietary science-based nutritional bioactive formulas for the food, dietary supplement, practitioner, direct selling and direct to consumer marketing channels.

About Optigenex Inc.:

Optigenex Inc. is a formulator, distributor and provider of proprietary next generation skin care technology, dietary supplements and bulk ingredient featuring AC-11® as its core product. AC-11® (formerly known as C-MED-100®) is a patented, bioactive and water soluble rain forest compound derived from the medicinal herb Uncaria tomentosa. For more information about Optigenex please visit our website: www.optigenex.com

*The statements made in this press release have not been evaluated by the Food and Drug Administration (FDA). The products mentioned herein are not intended to diagnose, treat, cure or prevent any disease.

Contact Information